Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Upgraded by Barclays to Hold Rating

Barclays upgraded shares of Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) from a strong sell rating to a hold rating in a research report report published on Thursday,Zacks.com reports.

Separately, Kepler Capital Markets upgraded Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy”.

Recordati Industria Chimica E Farmaceutica Stock Performance

Shares of Recordati Industria Chimica E Farmaceutica stock opened at $65.44 on Thursday. Recordati Industria Chimica E Farmaceutica has a fifty-two week low of $49.00 and a fifty-two week high of $65.44. The business’s fifty day moving average is $65.44 and its two-hundred day moving average is $65.44. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.64 and a quick ratio of 1.16.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.